2015 ACR/ARHP Annual Meeting

November 6-11, 2015. San Francisco, CA.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 2208

Macrophage Migration Inhibitory Factor: A Novel Biomarker in Ankylosing Spondylitis That Can Drive Spinal Fusion
Abstract Number: 424

Magnetic Resonance and Echocardiographic Strain Rate Imaging for the Early Detection of Cardiac Involvement in Juvenile Systemic Sclerosis
Abstract Number: 313

Magnetic Resonance Imaging Outcomes Using an Intra-Articular Injection (SM04690) in the Treatment of Osteoarthritis of the Knee: Interim, Exploratory Analysis of Results from a Randomized, Double-Blind, Placebo-Controlled, Phase 1 Study
Abstract Number: 2356

Major Cardiovascular Events in Gout Patients with Cardiovascular Disease or Heart Failure and Chronic Kidney Disease Initiating on Allopurinol or Febuxostat (Uloric)
Abstract Number: 2671

Male Gender and Higher Hemoglobin Predict Response to Methotrexate in Rheumatoid Arthritis
Abstract Number: 1684

Malignancies in Patients with Incident Psoriatic Arthritis 1970-2008 in Relation to a Comparator Cohort: A Population-Based Case-Control Study
Abstract Number: 571

Malignancy Data in Tofacitinib-Treated Japanese Patients with Rheumatoid Arthritis
Abstract Number: 1386

Malignancy Prevalence Is Increased Among Patients before the Onset of IgG4-Related Disease
Abstract Number: 399

Management of Lupus Anticoagulant Hypoprothrombinemia Syndrome in Juvenile Systemic Lupus Erythematosus – Single Center Experience
Abstract Number: 1044

Many Patients with Early Rheumatoid Arthritis Want Triple Therapy: An Analysis Combining Comparative Effectiveness Research and Patients Preferences to Inform Treatment Recommendations
Abstract Number: 779

Mapping Perceptions of Medication Decision Making Facilitators: The Importance of Patient Context
Abstract Number: 3143

Mapping the Back-Door Routes into the Vascular Wall: 3D Microscopic Reconstruction of Microvasculature in the Normal Temporal Artery and in Giant Cell Arteritis
Abstract Number: 1441

Marine Oil Supplements for Arthritis Pain: A Systematic Review and Meta-Analysis of Randomized Trials
Abstract Number: 1285

Markers of Non-Compliance with ASAS/EULAR Management Recommendations Among Early Spa Patients: Evidence over 3 Years in the DESIR Cohort
Abstract Number: 663

Mases Correlates Linearly with Disease Activity and Patient Related Outcomes in Patients with Axial Spondyloarthritis within the Scqm Cohort

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].